HWM
HBIO icon

HighMark Wealth Management’s Harvard Bioscience HBIO Stock Holding History

HighMark Wealth Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-280
Closed -$12K – 493
2020
Q4 		$12K Hold
280
– – 0.01% 202
2020
Q3 		$8K Sell
280
-4,819
-95% -$162K 0.01% 254
2020
Q2 		$158K Hold
5,099
– – 0.17% 43
2020
Q1 		$112K Hold
5,099
– – 0.14% 44
2019
Q4 		$155K Buy
+5,099
New +$147K 0.17% 45

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighMark Wealth Management's HBIO Position: Q1 2021 in Review

HighMark Wealth Management sold out of Harvard Bioscience (HBIO) in Q1 2021, closing a stake of 280 shares — an estimated $12K sold.

HighMark Wealth Management first reported a position in HBIO in Q4 2019 and held it in 5 quarters. The position peaked at $158K in Q2 2020. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2021.

  • HighMark Wealth Management reported no remaining Harvard Bioscience position as of Q1 2021 after selling out during the quarter.
  • HighMark Wealth Management sold 280 Harvard Bioscience shares in Q1 2021, an estimated $12K.
  • HighMark Wealth Management first reported a position in Harvard Bioscience in Q4 2019 and held it in 5 quarters.
  • HighMark Wealth Management's Harvard Bioscience position peaked at $158K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2021.

Based on HighMark Wealth Management's 13F filing for Q1 2021, filed 22 Apr 2021.